Immunome Inc (IMNM)

$26.97 +0.83 (3.18%)
Market Cap 2.26B
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,240.71%
Debt to Equity Ratio 0.00
Volume 1,989,200
Avg Vol 2,284,090
Day's Range N/A - N/A
Shares Out 91.71M
Stochastic %K 93%
Beta 2.22
Analysts Strong Sell
Price Target $34.50

Company Profile

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
HunterT
HunterT Feb. 3 at 11:22 PM
$IMNM the silent march to the 30s begins
0 · Reply
ripster47
ripster47 Jan. 23 at 12:18 PM
$IMNM 🚨 🚀 Big Winner from our Swing Idea from Last month See Before/After One of Repeatable Swing Setups taught by @ripster47 Biotech Swing See how price bounced from EMA Clouds & Support Level. Stop moved up Follow us for more Setups & Swing Charts at @TenetCharts
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 22 at 11:22 PM
The potential of radiopharmaceuticals in oncology $RADX $IMNM https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/unlocking-the-therapeutic-potential-of-radiopharmaceuticals-in-oncology
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 21 at 4:16 PM
$RADX Big time winner $SMMT $IMNM $PYXS
0 · Reply
RunnerSignals
RunnerSignals Jan. 20 at 9:12 PM
$PACB $SLS $CNTX $TXG $IMNM hit session lows but staged epic comebacks, closing well above their intraday bottoms
0 · Reply
redrussian
redrussian Jan. 20 at 7:29 PM
$IMNM out, thank you :). $$$
0 · Reply
alotobeer
alotobeer Jan. 20 at 4:34 PM
$IMNM Excellent job trapping the bears this morning, now we wait until they are forced to exit
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 12:49 AM
$IMNM Current Stock Price: $22.43 Contracts to trade: $20 IMNM Feb 20 2026 Call Entry: $3.40 Exit: $6.41 ROI: 89% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Jan. 15 at 9:26 PM
Red to Green Warriors $ASTS $NFE $STGW $IMNM $IPSC opened weak finished strong. Buyers showed up sellers blinked
0 · Reply
EingeLTrade
EingeLTrade Jan. 15 at 8:18 PM
$IMNM
0 · Reply
Latest News on IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:05 PM EST - 26 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 4 weeks ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Dec 17, 2025, 2:44 PM EST - 6 weeks ago

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Immunome Announces Pricing of Public Offering of Common Stock

Dec 16, 2025, 8:16 PM EST - 7 weeks ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 7 weeks ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:16 AM EST - 7 weeks ago

Immunome's experimental drug meets main goal in late-stage study

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 15, 2025, 7:00 AM EST - 7 weeks ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 7 weeks ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Immunome to Present at Upcoming Investor Conferences

Nov 25, 2025, 8:00 AM EST - 2 months ago

Immunome to Present at Upcoming Investor Conferences

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 31, 2025, 11:51 AM EDT - 3 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Oct 23, 2025, 12:00 PM EDT - 3 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 4 months ago

Infinimmune Announces Research Collaboration with Immunome

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 11, 2025, 10:31 PM EDT - 6 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 9 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 17, 2025, 6:06 AM EDT - 10 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 10 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 11 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 11 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 30, 2025, 10:27 AM EST - 1 year ago

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome: An Oncology Powerhouse In The Making

Apr 2, 2024, 2:07 PM EDT - 2 years ago

Immunome: An Oncology Powerhouse In The Making

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 28, 2024, 4:02 PM EDT - 2 years ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 18, 2024, 5:44 AM EDT - 2 years ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 7, 2024, 8:00 AM EST - 2 years ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

HunterT
HunterT Feb. 3 at 11:22 PM
$IMNM the silent march to the 30s begins
0 · Reply
ripster47
ripster47 Jan. 23 at 12:18 PM
$IMNM 🚨 🚀 Big Winner from our Swing Idea from Last month See Before/After One of Repeatable Swing Setups taught by @ripster47 Biotech Swing See how price bounced from EMA Clouds & Support Level. Stop moved up Follow us for more Setups & Swing Charts at @TenetCharts
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 22 at 11:22 PM
The potential of radiopharmaceuticals in oncology $RADX $IMNM https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/unlocking-the-therapeutic-potential-of-radiopharmaceuticals-in-oncology
0 · Reply
RadioIsotope25
RadioIsotope25 Jan. 21 at 4:16 PM
$RADX Big time winner $SMMT $IMNM $PYXS
0 · Reply
RunnerSignals
RunnerSignals Jan. 20 at 9:12 PM
$PACB $SLS $CNTX $TXG $IMNM hit session lows but staged epic comebacks, closing well above their intraday bottoms
0 · Reply
redrussian
redrussian Jan. 20 at 7:29 PM
$IMNM out, thank you :). $$$
0 · Reply
alotobeer
alotobeer Jan. 20 at 4:34 PM
$IMNM Excellent job trapping the bears this morning, now we wait until they are forced to exit
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 17 at 12:49 AM
$IMNM Current Stock Price: $22.43 Contracts to trade: $20 IMNM Feb 20 2026 Call Entry: $3.40 Exit: $6.41 ROI: 89% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
RunnerSignals
RunnerSignals Jan. 15 at 9:26 PM
Red to Green Warriors $ASTS $NFE $STGW $IMNM $IPSC opened weak finished strong. Buyers showed up sellers blinked
0 · Reply
EingeLTrade
EingeLTrade Jan. 15 at 8:18 PM
$IMNM
0 · Reply
Cryptocr7
Cryptocr7 Jan. 15 at 4:11 PM
$IMNM on the move 👀
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:28 PM
$IMNM RSI: 35.26, MACD: 0.2958 Vol: 1.06, MA20: 21.09, MA50: 19.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Cryptocr7
Cryptocr7 Jan. 13 at 7:38 PM
$IMNM could get a bump tomorrow and rest of the week with CEO at JPM Healthcare conference tomorrow
2 · Reply
RadioIsotope25
RadioIsotope25 Jan. 11 at 9:38 PM
$RADX strains more ownership in Radiopharm Ventures now at 87.5% yielding a basket of new therapeutics. B7-H3 created with the collaboration is now Phase 1 approved. Radiopharm Ventures = MD Anderson + Radiopharm Theranostics. Trading at 5-6% value of $AKTS with a more advanced diversified pipeline. $IMNM $MNPR
2 · Reply
W15E
W15E Jan. 11 at 4:30 PM
$IMNM 🤔
0 · Reply
EingeLTrade
EingeLTrade Jan. 9 at 5:31 PM
$IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 7 at 1:52 AM
$IMNM https://x.com/aponiaanalytics/status/2008612862349185166?s=46&t=9IU2_XHzwzFLsVH7RJTUPA
0 · Reply
redrussian
redrussian Jan. 6 at 6:32 PM
$IMNM added more (chairman acquired 5.8% more stock)also presenting today at a JPM healthcare conference
0 · Reply
EingeLTrade
EingeLTrade Jan. 6 at 3:26 PM
🔑 Key re-test month for $IMNM
0 · Reply
Elliotwavedave
Elliotwavedave Jan. 6 at 11:54 AM
$IMNM good ol Jim Cramer.
1 · Reply
TrendEdgeLogan
TrendEdgeLogan Jan. 3 at 4:31 PM
$IMNM $2.4B mc $XBI name seeing more UNPLANNED open mkt insider buys by President & CEO this pas week. $100K purchase, adding to this $1M purchase on 12/18/25. We have seen a ton of insider buying activity here over the past 2 years TrendEdge.app/asset/IMNM
1 · Reply
Smellmahass
Smellmahass Jan. 3 at 12:12 AM
$IMNM Oh dear had to sell for loss. Disappointed.
0 · Reply